Clinical Trials Browser

Active not recruiting × INDUSTRY × Cyclophosphamide × Clear all

NCT04106219 2026-04-21

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Phase 1 Active not recruiting

Epilepsy, Neuroblastoma

NCT03967223 2026-04-17

IGNYTE-ESO

Phase 2 Active not recruiting

Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT05888493 2026-04-17

LEDA

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT04623541 2026-04-13

EPCORE™ CLL-1

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04923893 2026-04-13

CARTITUDE-5

Phase 3 Active not recruiting

Multiple Myeloma

NCT06577025 2026-04-13

aMMbition

Phase 2 Active not recruiting

Multiple Myeloma

NCT04542824 2026-04-08

EPCORE™ NHL-3

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-04-08

EPCORE™ NHL-2

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05993299 2026-04-08

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

7 enrolled 15 charts

Neoplasms

NCT06703346 2026-04-08

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

Neoplasms

NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Phase 3 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT04824092 2026-04-01

frontMIND

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04529772 2026-03-31

ESCALADE

Phase 3 Active not recruiting

Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04629729 2026-03-19

FT819 in Subjects With B-cell Malignancies

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Phase 3 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT05624554 2026-03-16

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04931342 2026-03-10

BOUQUET

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT06045806 2026-03-05

KarMMa-9

Phase 3 Active not recruiting

Multiple Myeloma

NCT06961786 2026-03-05

TUNINTIL-2

Phase 1 Active not recruiting

Melanoma

NCT04416984 2026-03-04

ALPHA2

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT03407144 2026-02-19

MK-3475-667

Phase 2 Active not recruiting

Hodgkin Disease

NCT04980222 2026-02-17

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma

NCT06356129 2026-02-12

GOLSEEK-1

Phase 3 Active not recruiting

Lymphoma

NCT03274492 2026-02-06

POLARIX

Phase 3 Active not recruiting

1,000 enrolled 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT06097364 2026-02-06

OLYMPIA-2

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT06091865 2026-02-05

OLYMPIA-3

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06425302 2026-01-08

GOLSEEK-2

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Follicular

NCT06253663 2025-12-16

JKART-1

Phase 2 Active not recruiting

Recurrence, Lymphoma, Mantle-Cell

NCT04390399 2025-12-15

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04145349 2025-12-08

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Phase 1/2 Active not recruiting

30 enrolled 16 charts

Sarcoma, Desmoplastic Small Round Cell Tumor

NCT06285422 2025-11-28

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

Phase 1 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04245839 2025-11-05

TRANSCEND FL

Phase 2 Active not recruiting

276 enrolled 4 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT05371093 2025-10-15

ZUMA-22

Phase 3 Active not recruiting

Lymphoma, Follicular

NCT05878184 2025-10-02

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04696731 2025-09-25

TRAVERSE

Phase 1 Active not recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05492682 2025-09-05

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06480565 2025-08-15

A Phase 1/2 Trial of ADI-270 in ccRCC

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell

NCT05673785 2025-07-14

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Phase 2 Active not recruiting

Lymphoma

NCT03725059 2025-07-11

KEYNOTE-756

Phase 3 Active not recruiting

Breast Neoplasms

NCT05665062 2025-04-06

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Phase 1 Active not recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01903330 2025-03-05

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Phase 2 Active not recruiting

Glioblastoma, Gliosarcoma

NCT06093841 2025-02-11

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05578976 2025-01-23

EPCORE DLBCL-2

Phase 3 Active not recruiting

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03709680 2025-01-14

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Phase 2 Active not recruiting

Diffuse Intrinsic Pontine Glioma, Bone Neoplasms, Medulloblastoma, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Rhabdoid Tumor

NCT05201248 2025-01-07

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

Neoplasms, Lymphoma, B-Cell

NCT04623944 2024-12-27

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute